Targeted coating benefits Allvivo Vascular develops biomimetic coatings with nonthrombogenic, antibacterial, and anti-inflammatory properties, creating a compelling value proposition for medical device manufacturers seeking to reduce restenosis, infection, and long-term antiplatelet therapy requirements.

Stent coating opportunity ProteoGuard coating shows potential as an alternative to immune-suppressive and cytotoxic drugs for restenosis prevention, suggesting a direct sales angle with stent manufacturers looking to differentiate products and improve patient outcomes.

Strategic customer fit Given the small team and niche focus, align outreach with major device OEMs and contract manufacturers in cardiology and vascular interventional devices that prioritize thrombosis resistance, biocompatibility, and anti-inflammatory performance.

Technology readiness Utilize AWS, SQL, and standard web technologies to support scalable coatings data, traceability, and R&D collaboration; emphasize regulatory-friendly, data-backed performance claims to accelerate partnerships with large medical device players.

Commercial traction signals Revenue is currently under $1M, indicating early-stage commercial potential; pursue strategic partnerships, pilot programs, and co-development deals with large cap companies to validate clinical and economic value and unlock scale.